Review: Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)

Katelyn A. Pastick, Elizabeth C. Okafor, Fan Wang, Sarah M. Lofgren, Caleb P. Skipper, Melanie R. Nicol, Matthew F. Pullen, Radha Rajasingham, Emily G. McDonald, Todd C. Lee, Ilan S. Schwartz, Lauren E. Kelly, Sylvain A. Lother, Oriol Mitjà, Emili Letang, Mahsa Abassi, David R. Boulware

Research output: Contribution to journalReview article

2 Scopus citations


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.

Original languageEnglish (US)
Article numberofaa130
JournalOpen Forum Infectious Diseases
Issue number4
StatePublished - Mar 16 2020


  • “chloroquine
  • ” “SARS-CoV-2.”
  • ” “clinical trials
  • ” “coronavirus
  • ”“COVID-19
  • ”“Hydroxychloroquine

Fingerprint Dive into the research topics of 'Review: Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)'. Together they form a unique fingerprint.

  • Cite this